EP 1827494 A4 20100217 - COMBINATION GROWTH THERAPY AND CELL THERAPY FOR TREATMENT OF ACUTE AND CHRONIC DISEASES OF THE ORGANS
Title (en)
COMBINATION GROWTH THERAPY AND CELL THERAPY FOR TREATMENT OF ACUTE AND CHRONIC DISEASES OF THE ORGANS
Title (de)
KOMBINATIONSWACHSTUMSTHERAPIE UND ZELLTHERAPIE ZUR BEHANDLUNG VON AKUTEN UND CHRONISCHEN ORGANERKRANKUNGEN
Title (fr)
COMBINAISON DE THERAPIE AU FACTEUR DE CROISSANCE ET DE THERAPIE CELLULAIRE POUR LE TRAITEMENT DE MALADIES AIGUES ET CHRONIQUES DES ORGANES
Publication
Application
Priority
- US 2005041740 W 20051117
- US 99159204 A 20041118
- US 11485105 A 20050426
- US 17924505 A 20050712
Abstract (en)
[origin: WO2006055743A2] Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells or other cell therapy. The patient can be a fetus treated in utero or removed from the womb. The progress of treatment is monitored by ultrasound, MRI, CAT scan, cardiac echo, EEG, EKG, EMG or blood tests, with growth factor treatment and/or stem cell administration adjusted according to the results of the monitoring or clinical status of the patient. Organ disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation or intranasal therapy. Diseases affecting organs such as the brain, spinal cord, pancreas, liver, kidney, muscle, heart and upper and lower gastrointestinal tracts are treated using the present method. A device for treatment is disclosed. CPK is utilized to assess the treatment of muscle disease.
IPC 8 full level
A61K 38/18 (2006.01)
CPC (source: EP)
A61K 35/28 (2013.01); A61K 35/545 (2013.01); A61K 38/1825 (2013.01); A61K 38/1866 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); C12N 2710/10043 (2013.01)
Citation (search report)
- [XY] WO 2004009767 A2 20040129 - BOSTON SCIENT CORP [US]
- [XY] WO 02064157 A2 20020822 - BOSTON SCIENT CORP [US]
- [X] WO 03024478 A1 20030327 - NEURONOVA AB [SE], et al
- [Y] US 2002058612 A1 20020516 - FRANCO WAYNE P [US]
- [A] WO 9849300 A2 19981105 - COLLATERAL THERAPEUTICS [US]
- [A] US 2004048375 A1 20040311 - ALT ECKHARD [DE]
- [A] WO 0194420 A1 20011213 - UNIV COLUMBIA [US], et al
- [A] YLA-HERTTUALA SEPPO ET AL: "Gene transfer as a tool to induce therapeutic vascular growth.", NATURE MEDICINE, vol. 9, no. 6, June 2003 (2003-06-01), pages 694 - 701, XP002561932, ISSN: 1078-8956
- [A] MALECKI M ET AL: "VEGF165 AND FGF-2 for angiogenic gene therapy: a bicistronic strategy", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 11, no. Suppl. 1, 1 February 2004 (2004-02-01), pages S165 - S166, XP009125239, ISSN: 0969-7128
- See references of WO 2006055743A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2006055743 A2 20060526; WO 2006055743 A3 20080717; EP 1827494 A2 20070905; EP 1827494 A4 20100217
DOCDB simple family (application)
US 2005041740 W 20051117; EP 05823219 A 20051117